Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx

Sanofi has entered into a $1.7-billion deal to acquire Inhibrx, a company with a promising drug for Alpha-1 Antitrypsin Deficiency (AATD). The acquisition of Inhibrx will give Sanofi access to a potential treatment for AATD, a rare genetic disorder that can cause lung and liver damage. AATD affects approximately 100,000 people worldwide, with 90% of cases in the United States and Europe.

The deal highlights Sanofi's continued interest in expanding its presence in the pharmaceutical industry. In recent years, the company has been actively pursuing acquisitions and partnerships to strengthen its pipeline and grow its market share. For example, Sanofi signed a billion-dollar, multi-target artificial intelligence (AI) drug discovery deal with Insilico Medicine. The acquisition of Inhibrx further demonstrates Sanofi's commitment to investing in innovative medicines and expanding its product portfolio.

The AATD market is currently small, but it has the potential for significant growth as more effective treatments are developed and awareness of the condition increases. The acquisition of Inhibrx and its promising AATD treatment could position Sanofi as a leader in this emerging market, with the potential for substantial revenue growth in the future.